Hero image with Pittsburgh background pittplusme.org/study/1545

Pitt+Me HCC 19-059 - ICONIC Study


STUDY BASICS

Do you have a rare genitourinary (GU) tumor? If so, you may be eligible to participate in a study to help researchers test the good and bad effects of three combined cancer drugs, called cabozantinib, nivolumab, and ipilimumab, that are FDA-approved individually, but not in combination.


IRB:
  A031702 - Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Age Range
AGE:   18 and Up

Duration DURATION:  24 months of treatment & a follow-up period
VISITS:  Multiple

Location LOCATION: 
UPMC Hillman Cancer Centers in Greensburg, Monroeville, Passavant & Shadyside
Compensation COMPENSATION: 
None
Phone Number PHONE NUMBER:
1-866-438-8230
I'M INTERESTED
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   FacebookFacebook   TwitterTwitter   Linked-InLinked-In
Search Icon pittplusme.org/study/1545
OR
Phone Number PHONE NUMBER:
1-866-438-8230

PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe facebook twitter

Pitt+Me

This website is maintained by the Clinical and Translational Science Institute.
© Copyright 2018, University of Pittsburgh. All rights reserved.